Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

C3200000

Cyclobenzaprine hydrochloride

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

5-(3-Dimethylaminopropylidene)dibenzo[a,e]cycloheptatriene hydrochloride

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C20H21N · HCl
CAS Number:
6202-23-9
Molecular Weight:
311.85
MDL number:
MFCD00079039
UNSPSC Code:
41116107
PubChem Substance ID:
329775025
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

cyclobenzaprine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

Cl.CN(C)CC\C=C1\c2ccccc2C=Cc3ccccc13

InChI

1S/C20H21N.ClH/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20;/h3-6,8-14H,7,15H2,1-2H3;1H

InChI key

VXEAYBOGHINOKW-UHFFFAOYSA-N

Gene Information

human ... HTR2A(3356) , HTR2C(3358)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Cyclobenzaprine hydrochloride EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Skeletal muscle relaxant; reduces muscle spasm by depression of brainstem neurons; 5-HT2 serotonin receptor antagonist.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Pictograms

Skull and crossbones
GHS06

Signal Word

Danger

Hazard Statements

H301,H312 + H332

Hazard Classifications

Acute Tox. 3 Oral - Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Ney Carter Borges et al.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 879(31), 3728-3734 (2011-11-15)
In the present study a method to quantify chlorpromazine in human plasma using cyclobenzaprine as the internal standard (IS) is described. The analyte and the IS were extracted from human plasma by a liquid-liquid extraction with diethyl ether/dichloromethane (70/30, v/v)
Yi Xiang et al.
Biomedical chromatography : BMC, 26(9), 1083-1088 (2011-11-29)
A sensitive, rapid and simple liquid chromatography-electrospray ionization mass spectrometry (LC-ESI-MS/MS) method was developed for the quantitative determination of cyclobenzaprine in human plasma, to study the pharmacokinetic behavior of cyclobenzaprine capsule in healthy Chinese volunteers. With escitalopram as the internal
Harvey Moldofsky et al.
The Journal of rheumatology, 38(12), 2653-2663 (2011-09-03)
To determine the effects of bedtime very low dose (VLD) cyclobenzaprine (CBP) on symptoms and sleep physiology of patients with fibromyalgia (FM), unrefreshing sleep, and the α-nonREM sleep electroencephalographic (EEG) anomaly at screening. Of 37 patients with FM in the
Lindsay T Morgan Bicknell et al.
International journal of psychiatry in medicine, 44(4), 305-314 (2012-01-01)
Lamotrigine is FDA-approved as a maintenance treatment of bipolar disorder, but its common off-label uses include bipolar depression and antidepressant augmentation in patients with major depressive disorder. Among other adverse effects, cutaneous reactions, particularly erythema multiforme, are cited as concerns
Mona Darwish et al.
Clinical therapeutics, 33(6), 746-753 (2011-06-28)
The single-dose pharmacokinetic profile of cyclobenzaprine extended-release (CER) has been previously characterized and compared with the pharmacokinetics of cyclobenzaprine immediate-release (CIR) administered 3 times daily for 3 doses. The objective of this study was to characterize the multiple-dose pharmacokinetic properties
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service